RT Journal Article
SR Electronic
T1 Using genomic epidemiology of SARS-CoV-2 to support contact tracing and public health surveillance in rural Humboldt County, California
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.21.21258385
DO 10.1101/2021.09.21.21258385
A1 Stoddard, Gunnar
A1 Black, Allison
A1 Ayscue, Patrick
A1 Lu, Dan
A1 Kamm, Jack
A1 Bhatt, Karan
A1 Chan, Lienna
A1 Kistler, Amy L
A1 Batson, Joshua
A1 Detweiler, Angela
A1 Tan, Michelle
A1 Neff, Norma
A1 DeRisi, Joseph L
A1 Corrigan, Jeremy
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.21.21258385.abstract
AB During the COVID-19 pandemic within the United States, much of the responsibility for diagnostic testing and epidemiologic response has relied on the action of county-level departments of public health. Here we describe the integration of genomic surveillance into epidemiologic response within Humboldt County, a rural county in northwest California. Through a collaborative effort, 853 whole SARS-CoV-2 genomes were generated, representing ∼58% of the 1,449 SARS-CoV-2-positive cases detected in Humboldt County as of mid-March 2021. Phylogenetic analysis of these data was used to develop a comprehensive understanding of SARS-CoV-2 introductions to the county and to support contact tracing and epidemiologic investigations of all large outbreaks in the county. In the case of an outbreak on a commercial farm, viral genomic data were used to validate reported epidemiologic links and link additional cases within the community who did not report a farm exposure to the outbreak. During a separate outbreak within a skilled nursing facility, genomic surveillance data were used to rule out the putative index case, detect the emergence of an independent Spike:N501Y substitution, and verify that the outbreak had been brought under control. These use cases demonstrate how developing genomic surveillance capacity within local public health departments can support timely and responsive deployment of genomic epidemiology for surveillance and outbreak response based on local needs and priorities.Competing Interest StatementDr. DeRisi is a member of the scientific advisory board of The Public Health Company, Inc., and is a scientific advisor for Allen & Co. Dr. Batson became an employee of The Public Health Company, Inc. after the completion of the research described in the manuscript. None of the other authors declare any potential conflicts.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the University of California San Francisco Human Research Protection Program Institutional Review Board (IRB# 21-34522, Reference Number 319235). This same IRB also waived consent for specimen collection because collection occurred as part of public health response. All samples submitted to the Chan Zuckerberg Biohub for sequencing were de-identified. All genomic analysis was performed on de-identified genome sequences and sample metadata. All work was carried out in accordance with relevant regulations and guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Augur and Auspice components of the Nextstrain workflow are publicly available at https://github.com/nextstrain/. The SARS-CoV-2-specific Nextstrain phylogenetic pipeline is publicly available at https://github.com/nextstrain/ncov. The profile that specifies our particular parameters for this workflow is available at https://github.com/alliblk/ncov-humboldt. Scripts used in data analysis are also available at https://github.com/alliblk/ncov-humboldt. Whole genome sequences generated by CZ Biohub are available within GISAID and NCBI GenBank.